- Bacillus Calmette-Guérin (BCG) vaccination appears to prevent Mycobacterium tuberculosis (TB) acquisition in adult contacts and limits progression to latent tuberculosis infection (LTBI).
Why this matters
- Consider BCG vaccine history and time since vaccination in at-risk adults presenting post-TB exposure to facilitate best management strategies.
- Ensure familiarity with ECDC BCG vaccine scheduler.
- 3453 participants, 3399 included in complete-case analysis, median age 32 (interquartile range, 25-43) years.
- LTBI prevalence:
- 27.5% (951) overall;
- 27.0% (809) among vaccinated vs 31.4% (142) among unvaccinated;
- OR, 0.81 (P=.054).
- Multivariate, BCG-LTBI association:
- OR, 0.70 (P=.0017).
- Vaccine effectiveness (VE): 30% (95% CI, 13%-44%).
- BCG protection (ORs, 95% CIs) with vaccination at age
- 11-20 years ago: 0.55 (0.33-0.90);
- >20 years ago: 0.78 (0.60-1.00).
- ≤10 years ago: 0.31 (0.15-0.63);
- 11-20 years ago: 0.73 (0.48-1.10); and
- >20 years ago: 0.67 (0.46-0.98).
- Cross-sectional analysis assessing BCG VE durability against LTBI in at-risk, UK adults.
- Funding: National Institute for Health Research.
- Measurement errors, misclassifications.
- Self-report bias.
- Residual confounding.
- Interferon-gamma release assay (IGRA) specificity.